Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Surg Oncol Clin N Am. 2010 Jan;19(1):101–113. doi: 10.1016/j.soc.2009.09.004
# Patients
Randomized		 Study
Groups		 Stratification Significance
Demonstrated		 % Change Identified
in Trial
58 interrupted imatinib n = 32

continuous imatinib n = 26		 None Improvement in progression-free survival with continuous imatinib therapy versus interrupted imatinib therapy Median PFS 18 months (95% CI 15.0–23.6) vs. 18 months (95% CI 3.5–9.7), p < 0.0001)